Aktiebolaget Hassle v Biochemie Australia Pty Ltd

Aktiebolaget Hassle (Astra), the owner of a pharmaceutical patent, brought proceedings against Biochemie Australia Pty Ltd (Biochemie), a competitor in the market for proton pump inhibitors (PPIs), and others. The dispute involved issues of patent infringement and the potential for harm to Astra's business due to Biochemie's entry into the market. The case was heard in the Federal Court of Australia. The court was required to decide whether to grant interlocutory relief to Astra, in the form of an injunction or a freezing order, to prevent Biochemie from selling its product Probitor, which Astra claimed infringed its patent. The court also needed to balance the potential harm to Astra against the possible detriment to Biochemie and the public interest if the relief was granted. The court found that Astra, as the patent holder, was entitled to some protection of the status quo, but the unusual circumstances of the case, including the invalidity of the patent and Biochemie's entry into the market, lessened the weight of this principle. The court also considered the potential for Biochemie to lower the price of Probitor, which could affect the benchmark price for PPIs and harm Astra's business. However, the court noted that Biochemie had not made any immediate plans to lower the price and that there were other factors, such as other PPI distributors lowering their prices, that were beyond the control of both parties. The court concluded that, subject to certain conditions being met, it would dismiss Astra's application for interlocutory relief and stand the proceedings over to a later date to allow for those conditions to be addressed. The court also made an order that the proceedings be stood over until a date convenient to the parties.